Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan
When societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes.
Authors
- Jun Tsujimura
- Ayako Shoji (ORCID: https://orcid.org/0000-0002-1077-6393)
- Kentaro Higashi
- Naotaka Sakashita (ORCID: https://orcid.org/0000-0001-9608-1340)
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Yasuo Yanagi (ORCID: https://orcid.org/0000-0002-0362-7285)
- Shinya Ohno (ORCID: https://orcid.org/0000-0002-4157-9165)
Institutions
- National University of Singapore (SG)
- Singapore National Eye Center (SG)
- Tokyo Health Care University (JP)
- Chugai Pharma (United States) (US)
- Singapore Eye Research Institute (SG)
- Duke-NUS Medical School (SG)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- The University of Tokyo (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1080/13696998.2025.2478755
- Citations
- 4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.83